Molecular Actions of PPARα in Lipid ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
Titre :
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Auteur(s) :
Bougarne, Nadia [Auteur]
Weyers, Basiel [Auteur]
Desmet, Sofie [Auteur]
Deckers, Julie [Auteur]
Ray, David [Auteur]
Staels, Bart [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
de Bosscher, Karolien [Auteur correspondant]
Weyers, Basiel [Auteur]
Desmet, Sofie [Auteur]
Deckers, Julie [Auteur]
Ray, David [Auteur]
Staels, Bart [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
de Bosscher, Karolien [Auteur correspondant]
Titre de la revue :
Endocrine reviews
Pagination :
760-802
Éditeur :
Endocrine Society
Date de publication :
2018-10-01
ISSN :
0163-769X
Mot(s)-clé(s) en anglais :
metabolism 5 6
inflammation
molecular mechanism
fibrates
PPAR alpha
inflammation
molecular mechanism
fibrates
PPAR alpha
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
Résumé en anglais : [en]
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation ...
Lire la suite >Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.Lire moins >
Lire la suite >Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Projet ANR :
Source :
Fichiers
- https://www.hal.inserm.fr/inserm-02153118/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-02153118/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-02153118/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Bougarne%20Endocrine%20Review.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Bougarne%20Endocrine%20Review.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Bougarne%20Endocrine%20Review.pdf
- Accès libre
- Accéder au document